Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Duewell

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Leukemia|November 20, 2019
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockadeMichael Ruzicka, Lars M Koenig, Simone Formisano, et al.
Nature|April 30, 2010
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsPeter Duewell, Hajime Kono, Katey J Rayner, et al.
Science Immunology|July 17, 2021
OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosisDaniel F R Boehmer, Simone Formisano, Carina C de Oliveira Mann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2019
Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor ImmunotherapyClara H Karches, Mohamed-Reda Benmebarek, Moritz L Schmidbauer, et al.
Molecular Cancer Therapeutics|June 25, 2026
RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma modelCharlotte Marx, Julia Teppert, Laura Marisch, et al.
Cell|January 13, 2018
Western Diet Triggers NLRP3-Dependent Innate Immune ReprogrammingAnette Christ, Patrick Günther, Mario A R Lauterbach, et al.
Nature Biomedical Engineering|June 4, 2021
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumoursStefanie Lesch, Viktoria Blumenberg, Stefan Stoiber, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Leukemia|November 20, 2019
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockadeMichael Ruzicka, Lars M Koenig, Simone Formisano, et al.
Nature|April 30, 2010
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsPeter Duewell, Hajime Kono, Katey J Rayner, et al.
Science Immunology|July 17, 2021
OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosisDaniel F R Boehmer, Simone Formisano, Carina C de Oliveira Mann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2019
Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor ImmunotherapyClara H Karches, Mohamed-Reda Benmebarek, Moritz L Schmidbauer, et al.
Molecular Cancer Therapeutics|June 25, 2026
RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma modelCharlotte Marx, Julia Teppert, Laura Marisch, et al.
Cell|January 13, 2018
Western Diet Triggers NLRP3-Dependent Innate Immune ReprogrammingAnette Christ, Patrick Günther, Mario A R Lauterbach, et al.
Nature Biomedical Engineering|June 4, 2021
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumoursStefanie Lesch, Viktoria Blumenberg, Stefan Stoiber, et al.
Pageof 4